AstraZeneca and the University of Oxford have put a voluntary clinical trial hold on the Phase III trial testing their COVID-19 vaccine due to an adverse event. The companies confirmed the move in the evening on 8 September, only about a week after initiating the Phase III trial.
While the development of several COVID-19 vaccines across the industry has been moving at an unprecedented pace and remarkably smoothly...







